Evidence map›Paper›PMID 42673703›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2026

Impact of implementation process on long-acting cabotegravir/rilpivirine prescription at 9 HIV clinics, 2021-2024.

Sita Lujintanon, Catherine R Lesko, Nel Jason L Haw, Matthew D Hickey, Lauren C Zalla, Christin Kilcrease, Janet Grochowski, Lucas A Hill, Edward R Cachay, Jehan Z Budak and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Sita LujintanonJohns Hopkins University, Baltimore, MD, USA.ORCID 0000-0001-5380-2013
Catherine R LeskoJohns Hopkins University, Baltimore, MD, USA.
Nel Jason L HawJohns Hopkins University, Baltimore, MD, USA.
Matthew D HickeyUniversity of California, San Francisco, CA, USA.
Lauren C ZallaJohns Hopkins University, Baltimore, MD, USA.
Christin KilcreaseJohns Hopkins University, Baltimore, MD, USA.
Janet GrochowskiUniversity of California, San Francisco, CA, USA.
Lucas A HillUniversity of California, San Diego, CA, USA.
Edward R CachayMayo Clinic, Phoenix, AZ, USA.
Jehan Z BudakDivision of Allergy & Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA.
Heidi M CraneDivision of Allergy & Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA.
Julia FlemingFenway Institute and Harvard Medical School, Boston, MA, USA.
Kenneth H MayerFenway Institute and Harvard Medical School, Boston, MA, USA.
Sarah E RutsteinUniversity of North Carolina, Chapel Hill, NC, USA.
Barbarajean TurnerUniversity of North Carolina, Chapel Hill, NC, USA.
Christa NevinDivision of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA.
Greer A BurkholderDivision of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA.
Nan WangCase Western Reserve University, Cleveland, OH, USA.
George A YendewaCase Western Reserve University, Cleveland, OH, USA.
Ryan MossVanderbilt University Medical Center, Nashville, TN, USA.
April PettitVanderbilt University Medical Center, Nashville, TN, USA.
Allan E RodriguezUniversity of Miami, Miami, FL, USA.
Mallory O JohnsonUniversity of California, San Francisco, CA, USA.
Katerina A ChristopoulosUniversity of California, San Francisco, CA, USA.

Funding

Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4M
Mentoring Patient-Oriented Research on Advances to Optimize Engagement in HIV CareK24AI167805 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Katerina A Christopoulos · 2022 to 2026
$963k
Unhealthy alcohol use, other drug use, and mental health disorders: comorbidity burden in people with HIV, gaps in treatment, and impact on the HIV care continuumK01AA028193 · NIAAA · JOHNS HOPKINS UNIVERSITY · PI LESKO, CATHERINE · 2019 to 2023
$900k
NIAAA NIH HHS K01 AA028193NIAID NIH HHS K24 AI167805NIAID NIH HHS R24 AI067039
6 · The paper itself

Abstract

backgroundImplementation of long-acting cabotegravir/rilpivirine (LA-CAB/RPV) has been challenging and may limit its uptake. We describe the number of people with HIV (PWH) prescribed LA-CAB/RPV at 9 US academic HIV clinics in the Center for AIDS Research Network of Integrated Clinical Systems and clinic-level variation in LA-CAB/RPV prescriptions.

methodsUsing a sequential explanatory mixed methods design, we analyzed clinical cohort data of PWH prescribed LA-CAB/RPV, then conducted key informant surveys to ascertain each clinic's Exploration-Preparation-Implementation-Sustainment phase in conjunction with implementation determinants mapped to the Consolidated Framework for Implementation Research. We stratified the cohort analysis by phase.

resultsBetween 21-Jan-2021 and 30-Sep-2024, 1,451 (6%) of 22,379 PWH in care were prescribed LA-CAB/RPV. Among those prescribed, 15% had baseline viral load ≥200 copies/mL (200/1,451). Two sustainment-phase clinics that experienced fewer insurance-related barriers, planned prior to LA-CAB/RPV availability, had a pharmacy team coordinating LA-CAB/RPV services, and customized the electronic health record (EHR) system to track insurance approvals and/or injection appointments prescribed LA-CAB/RPV to 16% (924/5,638) of PWH in care. Four sustainment-phase clinics that had a mix of payor coverage and insurance plans, and adequate staffing prescribed to 3% (213/8,154). Three implementation-phase clinics with difficulty procuring LA-CAB/RPV due to restrictive insurance coverage and/or hospital policy and staffing challenges prescribed to 4% (314/8,587).

conclusionsBarriers related to insurance coverage and drug procurement impacted the number of PWH prescribed LA-CAB/RPV as did processes to plan for, and adapt to, these barriers. Scale-up efforts should consider team coordination and EHR-facilitated tracking to support the growing number of PWH on LA-CAB/RPV.

Indexed as

HIVimplementation processimplementation scienceimplementation strategieslong-acting cabotegravir/rilpivirine

Identifiers

PMID42673703
PMCPMC13533443

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.